Clinical Trials Browser

Osteosarcoma × trastuzumab deruxtecan × 90 days × Clear all

NCT04616560 2026-05-13

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

Phase 2 Suspended

Osteosarcoma